Dr. Ansell on Combining CAR T-cell Therapy and Immunotherapy in Lymphomas

Video

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

A therapeutic approach like this is definitely an option in lymphomas, Ansell explains. CAR T cells are highly effective therapies and are very promising; however, the significant activation often results in exhaustion. An important component might be to reverse exhaustion or prevent it, which can be done with immune checkpoint therapies.

The challenge, however, is to balance that with the potential toxicities, he adds. Researchers will learn how to manage combinations, Ansell predicts, adding he sees this having great promise in the future.

Related Videos
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
© 2024 MJH Life Sciences

All rights reserved.